Results 11 to 20 of about 89,572 (287)

Docetaxel-related interstitial pneumonitis

Therapeutics and Clinical Risk Management, 2015
Chung-Jen Wang, Hou-Tai Chang, Cheng-Yu Chang Division of Chest Medicine, Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan Abstract: Docetaxel (Taxotere®) is an agent that is indicated for the treatment of ...
Wang CJ, Chang HT, Chang CY
doaj   +1 more source

Protective Effect of Docetaxel Against Autophagy-Related Genes in Vitrification of Mouse Metaphase II Oocytes [PDF]

Iranian Journal of Medical Sciences, 2023
Background: Autophagy is a conservative mechanism for cell survival as the main response of cells to stress conditions. The present study aimed to assess the effect of docetaxel on the survival, fertilization, and expression of autophagy-related genes in
Hamed Daneshpazhouh, Nasim Hayati Roodbari, Yaser Tahamtani, Zahra Khodabandeh, Mehdi Dianatpour   +4 more
doaj   +1 more source

Life-Threatening Docetaxel Toxicity in a Patient With Reduced-Function CYP3A Variants: A Case Report

Frontiers in Oncology, 2022
Docetaxel therapy occasionally causes severe and life-threatening toxicities. Some docetaxel toxicities are related to exposure, and inter-individual variability in exposure has been described based on genetic variation and drug-drug interactions that ...
Nicholas R. Powell, Tyler Shugg, Reynold C. Ly, Costantine Albany, Milan Radovich, Bryan P. Schneider, Todd C. Skaar   +6 more
doaj   +1 more source

Efficacy and Safety of Dual Anti-HER2 Blockade and Docetaxel With or Without Carboplatin as Neoadjuvant Regimen for Treatment of HER2-Positive Breast Cancer

Technology in Cancer Research & Treatment, 2023
Introduction: This study aimed to compare the efficacy and safety of docetaxel + trastuzumab + pertuzumab and docetaxel + carboplatin + trastuzumab + pertuzumab for treating HER2-positive breast cancer.
Binwei Lin MM, Jinjia Fan MM, Fang Liu MD, Yixue Wen MM, Jie Li MD, Feng Gao MD, Yu Zhang MD, Gang Feng MM, Xiaobo Du MD, Wenzhi Chen MD   +9 more
doaj   +1 more source

Safety and pharmacokinetics of docetaxel in combination with pegvorhyaluronidase alfa in patients with non‐small cell lung cancer

Clinical and Translational Science, 2021
This open‐label, phase Ib study (NCT02346370) assessed the effect of pegvorhyaluronidase alfa (PVHA; PEGPH20) on the plasma pharmacokinetics (PKs) and safety of docetaxel in 15 patients with stage IIIB/IV non‐small cell lung cancer (NSCLC). The docetaxel
Thomas Heineman, Megan Baumgart, Charvi Nanavati, Nash Gabrail, Scott A. Van Wart, Donald E. Mager, Daniel C. Maneval, Anas M. Fathallah, Rose E. Sekulovich   +8 more
doaj   +1 more source

Efficacy of neoadjuvant docetaxel + cisplatin chemo-hormonal therapy versus docetaxel chemo-hormonal therapy in patients with locally advanced prostate cancer with germline DNA damage repair gene alterations

Therapeutic Advances in Medical Oncology, 2022
Purpose: To assess the efficacy and safety of neoadjuvant docetaxel + cisplatin chemotherapy with androgen deprivation therapy for the treatment of locally advanced prostate cancer (PCa) in patients harboring germline DNA damage repair genes (gDDR ...
Chenfei Chi, Jiazhou Liu, Liancheng Fan, Yinjie Zhu, Yanqing Wang, Jianjun Sha, Yiran Huang, Baijun Dong, Jiahua Pan, Wei Xue   +9 more
doaj   +1 more source

Docetaxel rechallenge in metastatic castration-resistant prostate cancer: A retrospective, single-center study [PDF]

Investigative and Clinical Urology, 2020
Purpose: To assess the efficacy and safety of docetaxel rechallenge in the salvage setting in metastatic castration-resistant prostate cancer (mCRPC) patients. Materials and Methods: Clinicopathologic data from patients treated with docetaxel rechallenge
Seonggyu Byeon , Hyera Kim , Jinchul Kim , Minsuk Kwon , Joon Young Hur , Hwang Gyun Jeon , Seong Soo Jeon , Hyun Moo Lee , Se Hoon Park   +8 more
doaj   +1 more source

δ-Tocopherol Enhances Docetaxel-Induced Growth Inhibition and Apoptosis in Ovarian Cancer SKOV3 Cells

Natural Product Communications, 2021
Docetaxel is the first-line chemotherapeutic drug for ovarian cancer. However, its clinical use is limited owing to its serious side effects. Therefore, it is of great clinical significance to enhance the efficacy of docetaxel at lower doses in a less ...
Hongjuan Chai, Jugang Wu, Junlei Liu, Ting Liu, Qing Ren, Xi Zheng   +5 more
doaj   +1 more source

No relation between docetaxel administration route and high‐grade diarrhea incidence

Pharmacology Research & Perspectives, 2020
Oral administration of docetaxel in combination with the CYP3A4 inhibitor ritonavir is used in clinical trials to improve oral bioavailability of docetaxel. Diarrhea was the most commonly observed and dose‐limiting toxicity.
Jeroen J. M. A. Hendrikx, Frederik E. Stuurman, Ji‐Ying Song, Vincent A. deWeger, Jurjen S. Lagas, Hilde Rosing, Jos H. Beijnen, Alfred H. Schinkel, Jan H. M. Schellens, Serena Marchetti   +9 more
doaj   +1 more source

CD44v8-10 mRNA contained in serum exosomes as a diagnostic marker for docetaxel resistance in prostate cancer patients

Heliyon, 2020
Background: Docetaxel is first-line chemotherapy for castration-resistant prostate cancer (CRPC), but most patients acquire docetaxel resistance. CD44 has been shown to be involved in drug resistance of cancers including prostate cancer.
Taku Kato, Kosuke Mizutani, Kyojiro Kawakami, Yasunori Fujita, Hidetoshi Ehara, Masafumi Ito   +5 more
doaj   +1 more source